Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production by Capuano, Cristina et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=koni20
Download by: [Universita Studi la Sapienza] Date: 26 April 2017, At: 03:39
OncoImmunology
ISSN: (Print) 2162-402X (Online) Journal homepage: http://www.tandfonline.com/loi/koni20
Obinutuzumab-mediated high-affinity ligation of
FcγRIIIA/CD16 primes NK cells for IFNγ production
Cristina Capuano, Chiara Pighi, Rosa Molfetta, Rossella Paolini, Simone
Battella, Gabriella Palmieri, Giuseppe Giannini, Francesca Belardinilli,
Angela Santoni & Ricciarda Galandrini
To cite this article: Cristina Capuano, Chiara Pighi, Rosa Molfetta, Rossella Paolini, Simone
Battella, Gabriella Palmieri, Giuseppe Giannini, Francesca Belardinilli, Angela Santoni & Ricciarda
Galandrini (2017) Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells
for IFNγ production, OncoImmunology, 6:3, e1290037, DOI: 10.1080/2162402X.2017.1290037
To link to this article:  http://dx.doi.org/10.1080/2162402X.2017.1290037
© 2017 The Author(s). Published with
license by Taylor & Francis Group, LLC©
Cristina Capuano, Chiara Pighi, Rosa
Molfetta, Rossella Paolini, Simone Battella,
Gabriella Palmieri, Giuseppe Giannini,
Francesca Belardinilli, Angela Santoni, and
Ricciarda Galandrini
View supplementary material 
Accepted author version posted online: 10
Feb 2017.
Published online: 10 Feb 2017.
Submit your article to this journal 
Article views: 277 View related articles 
View Crossmark data
ORIGINAL RESEARCH
Obinutuzumab-mediated high-affinity ligation of FcgRIIIA/CD16 primes NK cells for
IFNg production
Cristina Capuanoa,*, Chiara Pighib,*, Rosa Molfettab, Rossella Paolinib, Simone Battellab, Gabriella Palmieria,
Giuseppe Giannini b, Francesca Belardinilli b, Angela Santonib,c, and Ricciarda Galandrinia
aDepartment of Experimental Medicine, Laboratorio Pasteur Italia Fondazione Cenci Bolognetti, Sapienza University, Rome, Italy; bDepartment of
Molecular Medicine, Laboratorio Pasteur Italia Fondazione Cenci Bolognetti, Sapienza University, Rome, Italy; cIRCCS Neuromed, Pozzilli, Italy
ARTICLE HISTORY
Received 7 December 2016
Revised 24 January 2017
Accepted 26 January 2017
ABSTRACT
Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), based on the
recognition of IgG-opsonized targets by the low-affinity receptor for IgG FcgRIIIA/CD16, represents one of
the main mechanisms by which therapeutic antibodies (mAbs) mediate their antitumor effects. Besides
ADCC, CD16 ligation also results in cytokine production, in particular, NK-derived IFNg is endowed with a
well-recognized role in the shaping of adaptive immune responses.
Obinutuzumab is a glycoengineered anti-CD20 mAb with a modified crystallizable fragment (Fc)
domain designed to increase the affinity for CD16 and consequently the killing of mAb-opsonized targets.
However, the impact of CD16 ligation in optimized affinity conditions on NK functional program is not
completely understood.
Herein, we demonstrate that the interaction of NK cells with obinutuzumab-opsonized cells results in
enhanced IFNg production as compared with parental non-glycoengineered mAb or the reference
molecule rituximab. We observed that affinity ligation conditions strictly correlate with the ability to
induce CD16 down-modulation and lysosomal targeting of receptor-associated signaling elements.
Indeed, a preferential degradation of FceRIg chain and Syk kinase was observed upon obinutuzumab
stimulation independently from CD16-V158F polymorphism. Although the downregulation of FceRIg/Syk
module leads to the impairment of cytotoxic function induced by NKp46 and NKp30 receptors,
obinutuzumab-experienced cells exhibit an increased ability to produce IFNg in response to different
stimuli.
These data highlight a relationship between CD16 aggregation conditions and the ability to promote a




FcgRIIIA/CD16; IFNg ; NK
cells; obinutuzumab
Introduction
Therapeutic monoclonal antibodies (mAbs) have revolution-
ized the treatment of many types of cancer. In particular, rituxi-
mab anti-CD20 mAb-based chemoimmunotherapy regimens
have represented a breakthrough in the treatment of several B
cell malignancies, and now constitute the front-line therapy for
B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin
lymphomas.1 Rituximab also stands as the reference molecule
for the comparison with new generation anti-CD20 mAbs,
designed to overcome rituximab refractoriness and to reach
greater clinical efficacy.2 Among them, obinutuzumab is now
approaching the clinical use as a first line therapy for previously
untreated CLL and for rituximab-refractory indolent lympho-
mas.3,4 Obinutuzumab is a third-generation, type II, humanized
IgG1k mAb that binds to a CD20 epitope in a different space
orientation and with a wider elbow-hinge angle compared with
rituximab.5 Obinutuzumab was glycoengineered by removing
core fucose in the crystallizable fragment (Fc) portion of the
mAb. This modification substantially enhances the binding
affinity to FcgRIIIA/CD16, thus improving antibody-depen-
dent cell-mediated cytotoxicity (ADCC)6,7 and antibody-
dependent cell-mediated phagocytosis (ADCP).8,9 As a type II
antibody, obinutuzumab antitumor effects mostly rely on
ADCC and direct cytotoxic effects; in contrast, type I mAbs
(rituximab and ofatumumab) display stronger complement-
dependent cytotoxicity and minimal direct cytotoxicity.9-11
The relative contribution of ADCC and ADCP to the antitu-
mor activity of anti-CD20 antibodies has been addressed by
several groups. In murine models, different studies report a pri-
mary role for phagocytic mechanisms in antitumor activity
induced by both class I and class II anti-CD20 mAbs.12-14
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However, others have demonstrated the importance of mAb-
mediated NK cell activation especially in long-term antitumor
protection, suggesting that the mechanism of action may vary
depending on the tumor model and location.15,16
CD16 is expressed on various immune effector cells,
namely macrophages, monocytes and natural killer (NK)
cells.17 The impact of a FCGR3A polymorphism in predict-
ing the clinical response to rituximab treatment in patients
with Follicular Lymphoma highlights the relevance of such
receptor in antitumor activity.18,19 Specifically, the relevant
genetic variant of FCGR3A gene consists of a polymor-
phism present on aminoacid position 158 (c.559G>T, p.
Phe158Val) predicting a lower affinity form with a phenyl-
alanine (FcgRIIIA-158F) or a higher affinity form with a
valine (FcgRIIIA-158V).20 In vitro evidence demonstrated
that Fc glycoengineering confers the ability to achieve
higher ADCC even in individuals harboring the low-affinity
CD16 allotype (FcgRIIIA-158F), thus overcoming the prob-
lem of individual heterogeneity in FCGR3A polymorphisms
and therapy responses.21,22 Moreover, multiple lines of evi-
dence have shown the inhibitory killer cell immunoglobulin
like receptor (KIR)/HLA interactions do not negatively
impact on obinutuzumab-mediated target cell depletion.21
CD16 represents the prototype of NK activating receptors;
its engagement by IgG-opsonized targets is sufficient to trigger
ADCC as well as the production of pro-inflammatory cytokines
and chemokines (such as IFNg, TNF, IL-6, GM-CSF and
CCL5).23,24 Among them, IFNg stands as a well-recognized key
immunoregulatory factor in the shaping of antitumor adaptive
immune responses by modulating the responses of dendritic
cells (DCs) and T cells.25-27
In human NK cells, CD16 exhibits two extracellular Ig
domains, a short cytoplasmic tail and a trans-membrane
domain that enables its association with immune-receptor tyro-
sine-based activation motif (ITAM)-containing CD3z and
FceRIg chains,28 which guarantee Syk- and ZAP-70-dependent
signal transduction.24 Notably, CD3z and FceRIg chains are
also associated with the natural cytotoxicity receptors (NCRs),
such as NKp46 and NKp30.29 Together with NCRs, other natu-
ral activating receptors including the lectin-like receptor
NKG2D, the signaling lymphocyte-activation molecule
(SLAM) family member 2B4, the Ig-like receptor DNAM-1
participate to the recognition of a multitude of ligands
expressed on infected and tumor cells, playing an important
role in antitumor response and immune-surveillance.24
In a recent study, we demonstrated that following CD16
stimulation by rituximab-opsonized targets, hence under low-
affinity conditions, NK cells became unable to further kill target
cells either via antibody-dependent or natural cytotoxicity.30
In this study, we have compared the impact of exposure of
primary NK cells to rituximab or obinutuzumab, in both its
glycoengineered and non-glycoengineered wild type (wt) form,
on NK cell functions and responsiveness.
Using an in vitro setting, we observed that obinutuzu-
mab, by virtue of its increased affinity for CD16, besides
increasing ADCC also induces a significant enhancement of
IFNg production. Notably, the affinity ligation conditions
strictly correlate with the ability to induce CD16 down-
modulation and lysosomal targeting of receptor-associated
signaling elements. Indeed, a preferential degradation of
FceRIg chain and Syk kinase is observed upon obinutuzu-
mab stimulation independently from CD16-V158F polymor-
phism. Although the downregulation of FceRIg/Syk module
leads to the impairment of cytotoxic function induced by
NKp46 and NKp30 receptors, the ability of obinutuzumab-
experienced cells to produce IFNg in response to cytokines,
target stimulation as well as obinutuzumab-mediated CD16
re-stimulation, is enhanced.
Overall, our data indicate that CD16 aggregation conditions
may dictate both the amplitude of NK responsiveness and the
ability to shift NK functional program.
Results
CD16 engagement by obinutuzumab-opsonized targets
results in enhanced cytotoxicity and IFNg production in
primary human NK cells
Although the enhancement of NK cell-mediated ADCC toward
obinutuzumab-coated targets is well described,6,11,21 the impact
of mAb defucosylation on the ability to induce NK-derived
IFNg production has not been explored yet.
To analyze at what extent individual NK cells can be
induced to perform degranulation and/or cytokine produc-
tion, the intracellular expression of IFNg and surface
expression of CD107a (marker of lytic granule exocytosis)
were simultaneously assessed on peripheral blood
CD3¡CD56C NK cells by multicolour cytofluorimetric anal-
ysis. Hereafter, in all our experimental settings, we obtained
the stimulation of CD16 by co-culturing NK cells with
CD20C B cell lymphoma Raji cells that were opsonized
with rituximab or obinutuzumab, in the defucosylated
(GA101) or wild type version (wt-GA101), at saturating
concentration as detailed in Materials and methods section
and Fig. S1. Being Raji cells almost completely resistant to
freshly isolated NK-mediated killing, the stimulation with
non-opsonized Raji does not induce significant IFNg pro-
duction or CD107a expression (Fig. 1A and B). The stimu-
lation of NK cells with rituximab-opsonized targets induces
both degranulation and IFNg production with a slightly
greater frequency of CD107aC than of IFNgC cells, confirm-
ing the hierarchy among NK cell responses described previ-
ously.31 Under such stimulation conditions, only 11% of the
cells on average were able to perform both responses. Nota-
bly, when NK cells were stimulated with obinutuzumab-
opsonized targets both degranulation and IFNg production
appeared significantly enhanced with respect to rituximab.
Importantly, the percentage of NK cells that acquired the
ability to degranulate and to produce IFNg results almost
twice in response to obinutuzumab than to rituximab. The
enhanced activity of obinutuzumab is for large part attribut-
able to defucosylation, in fact, wt-GA101 behaves similarly
to rituximab in inducing NK functions. Besides the
increased portion of IFNg producing cells, the analysis of
median values demonstrates that obinutuzumab stimulation
increases the IFNg quantity on a per cell basis (Fig. 1C).
On the same line, when we assessed the ability of primary
cultured NK cells to kill anti-CD20-opsonized targets or to
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produce IFNg, we observed higher responses in cells stimulated
with obinutuzumab with respect to rituximab (Fig. S2).
Together these data demonstrate that, by virtue of defucosyla-
tion, obinutuzumab induces a comprehensive improvement of
NK cell responses also inducing multiple effector responses in
individual cells.
CD16 engagement by obinutuzumab-opsonized targets
promotes an enhanced receptor down-modulation and
lysosomal targeting
We recently described the down-modulation of CD16 receptor
complex upon its engagement by rituximab-opsonized tar-
gets.30 To compare the kinetics of CD16 down-modulation
induced by rituximab or obinutuzumab,we evaluated CD16 lev-
els in the course of the interaction with anti-CD20-opsonized
targets. Surface CD16 levels were assessed by staining with
B73.1 mAb whose binding to CD16 is not affected by Fc mask-
ing.32 For each time of stimulation, we kept as 100% CD16 lev-
els of sample stimulated with non-opsonized targets. Our data
(Fig. 2A) show a progressive and marked CD16 down-modula-
tion in NK cells interacting with anti-CD20-opsonized targets
(Fig. 2A, right panel). Notably, the stimulation with obinutuzu-
mab promotes a more rapid and profound CD16 down-modu-
lation, reaching almost 17% of initial levels (vs 40% in
rituximab-stimulated cells). In wt-GA101-stimulated cells, the
kinetics of CD16 downregulation appears slower and overall
less efficient, evidencing the role of the increased CD16 affinity
binding. We also addressed the persistence of CD16 down-
modulated status by monitoring its expression levels in NK
cells that were immunomagnetically isolated upon 18 h co-
cultures with anti-CD20-opsonized targets (hereafter “experi-
enced cells”) and maintained in culture for different lengths of
time. Under such conditions, we observed a progressive recov-
ery of CD16 expression that was complete after 48 h of culture
(Fig. S3).
Then, we evaluated the fate of internalized CD16 by
studying its re-distribution in lysosomal compartment by
confocal fluorescence microscopy. Primary cultured NK
cells were allowed to interact with anti-CD20-opsonized tar-
gets for 15 min, and LysoTracker was used to visualize lyso-
somes. As compared with the ring pattern observed in
unstimulated cells, CD16 distributed in intracellular dots in
cells interacting with rituximab- or obinutuzumab-opson-
ized targets (Fig. 2B). The analysis of 50 E/T conjugates in
randomly acquired fields reveals that a substantial portion
of internalized CD16 co-localizes with lysosomes. Interest-
ingly, we observed that the percentage of cells with CD16/
lysosome co-localization was significantly higher in NK cells
conjugated to obinutuzumab-opsonized cells with respect to
those interacting with rituximab- or wt-GA101-opsonized
targets (Fig. 2C).
This data demonstrate that obinutuzumab, by virtue of defu-
cosylation, promotes an increased rate of CD16 down-modula-
tion associated with an enhanced lysosomal targeting.
Preferential occurrence of FceRIg degradation upon
obinutuzumab-coated target interaction: Impact of
FCGR3A-V158F polymorphism
We sought to analyze whether the FCGR3A c.559G>T poly-
morphism would impact on CD16 dynamics. V158F single
nucleotide polymorphism was determined by cytofluorimetric
Figure 1. CD16 engagement by obinutuzumab-opsonized targets enhances both CD107a mobilization and IFNg production. PBMCs were left alone (baseline) or com-
bined (2:1) with rituximab (Raji-RTX)-, obinutuzumab (Raji-GA101)-, wt-GA101 (Raji-wt-GA101)-opsonized or non-opsonized Raji (Raji-Ctrl) for 6 h. The percentage of
IFNgC and CD107aC cells among NK cells (CD3¡CD56C) were analyzed by flow cytometry. (A) Plots from one representative donor are shown. (B) Data (mean § SEM)
from nine donors are shown. p < 0.05, p < 0.01, p < 0.0001. Compared to baseline or Raji-Ctrl samples, all the differences were statistically significant (p <
0.0001). (C) The median fluorescence intensity (FI) values of IFNg NK cells from nine individuals are reported in the graph. Each line represents a single donor. p < 0.01,
p < 0.0001.
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approaches33 and confirmed by a PCR-based analysis.34,35 Of
the 125 typed donors, 21 and 34 were V/V and F/F homozy-
gous, respectively, while 70 were V/F heterozygous, testifying a
large prevalence of individuals at intermediate–high affinity. In
line with previous observations demonstrating that obinutuzu-
mab triggers an enhanced ADCC irrespective of CD16 allo-
type,21,22 we observed that in F/F individuals surface CD107a
levels in response to obinutuzumab were significantly higher
with respect to rituximab, although lower than V/F or V/V
donors (Fig. 3A).
We then compared the ability of rituximab and obinutuzu-
mab to modulate CD16 levels among different allotypes. Upon
a sustained receptor stimulation (18 h) we observed that rituxi-
mab-induced CD16 down-modulation is less efficient in F/F
donors than in V/F and V/V donors, which behave similarly.
By contrast, when we stimulated NK cells with obinutuzumab-
opsonized targets, receptor downregulation was stronger and
not significantly affected by CD16 allotype (Fig. 3B).
CD3z and FceRIg chains associate to CD16 receptor in NK
cells as homo or heterodimers, being g/g homodimers the pre-
dominant species.28 The biochemical analysis of CD3z and
FceRIg chains in anti-CD20-experienced NK cells reveals that
obinutuzumab, but not rituximab, promotes a marked and
selective reduction of FceRIg chain levels in F/F donors, being
CD3z only marginally affected (Fig. 3C and D). Differently,
both obinutuzumab and rituximab induce FceRIg and, at a
lower degree, CD3z downregulation in V/F or V/V donors
(Fig. 3E and F). The reduction of FceRIg and CD3z is, at least
for a consistent part, attributable to lysosomal degradation as
the treatment with ammonium chloride (NH4Cl), which inhib-
its lysosome functions, in part prevents such response
(Fig. 3C–F).
Focusing our analysis on V/F and V/V donors in which both
FceRIg and CD3z undergo degradation, we observed that the
degradative pathway involves other CD16-activated signaling
elements since Syk, but not ZAP-70, kinase levels are signifi-
cantly reduced in anti-CD20-experienced NK cells (Fig. S4A).
Since we previously demonstrated the contribution of the ubiq-
uitin pathway in Syk degradation induced by anti-CD16-trig-
gered receptor engagement,36 we investigated whether Syk
undergoes ubiquitin modification in response to anti-CD20
mAb stimulation. NK cells were stimulated with fixed anti-
CD20-opsonized targets and tyrosine phosphorylated and
ubiquitinated Syk levels were analyzed in Syk immunoprecipi-
tates. In such experiments, we introduced, as a further negative
control, the obinutuzumab Fab fragment as an antibody that
lacks the ability to bind to CD16. Receptor engagement rapidly
induces a typical pattern of Syk tyrosine phosphorylation that
appears as multiple molecular species showing a regular molec-
ular weight increase suggestive of ubiquitination. Indeed,
Figure 2. CD16 engagement by anti-CD20-opsonized targets induces receptor down-modulation and lysosomal targeting. (A) Primary cultured NK cells were combined
(2:1) for the indicated times with rituximab (Raji-RTX)-, obinutuzumab (Raji-GA101)-, wt-GA101 (Raji-wt-GA101)-opsonized or non-opsonized Raji (Raji-Ctrl). CD16 surface
expression was evaluated by FACS analysis by anti-CD16 (Leu11c) mAb gating on CD56C population. (Left panels) The overlays of histograms from one representative
experiment are shown. (Right panel) Normalized CD16 MFI was calculated as follows: (MFI of the stimulated sample/MFI of Ctrl sample) £ 100, assuming as 100% the MFI
value of NK cells co-cultured with non-opsonized (Raji-Ctrl) targets for each time of stimulation. Data (mean § SEM) from six independent experiments are shown. p <
0.05. (B) LysoTracker-labeled NK cells (red) were combined (2:1) for 15 min with CMAC-labeled rituximab (NK/Raji-RTX)-, obinutuzumab (NK/Raji-GA101)- or wt-GA101
(NK/Raji-wt-GA101)-opsonized targets (blue). Cell conjugates were fixed, permeabilized and stained with anti-CD16 (B73.1) followed by Alexa Fluor 488-GAM (green) Abs.
A representative image of NK/target conjugate and isolated NK cell are shown. The overlay of the three-color merged image and the differential interference contrast
(DIC) is shown. Scale bar, 5 mm. (C) The percentage of conjugates containing CD16/lysosome co-localization (Pearson’s correlation coefficient > 0.2) was analyzed on ran-
domly acquired fields of three independent experiments (mean § SEM; n D 50 conjugates). p < 0.05, p < 0.01.
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immunoblotting with anti-ubiquitin mAb visualizes multiple
bands in the region of phosphorylated Syk. Notably, Syk ubiq-
uitination signal appears more persistent and stronger in obi-
nutuzumab- than in rituximab-stimulated samples (Fig. S4B).
Overall, the data demonstrate that in CD16 intermediate/
high affinity donors both antibodies behave similarly in induc-
ing the degradation of FceRIg, and to a lesser extent of CD3z
and of Syk kinase, whereas, only obinutuzumab stimulation
activates a degradative pathway selectively involving FceRIg, in
low-affinity donors.
NK cell interaction with anti-CD20-opsonized targets
results in the impairment of NKp46- and NKp30-dependent
cytotoxic response
We then investigated the functional outcome of the sustained
CD16 ligation to mimic the chronic NK stimulation occurring
in mAb-treated patients. In particular, we addressed whether
the internalization of CD16 receptor complex leading to
reduced levels of FceRIg, CD3z and Syk kinase would impact
on NK cytolytic potential.
Figure 3. CD16 engagement by obinutuzumab-opsonized targets results in enhanced degranulation as well as FceRIg lysosomal degradation irrespective of FCGR3A-
V158F polymorphism. (A) PBMCs were left alone (baseline) or allowed to interact (2:1) with rituximab (Raji-RTX)-, obinutuzumab (Raji-GA101)-opsonized or non-opsonized
Raji (Raji-Ctrl) for 6 h. The percentage of CD107aC cells among CD3¡CD56C was evaluated by FACS analysis in individuals grouped by FCGR3A genotype (high-affinity
allele V, low-affinity F; V/V, n D 6; V/F, n D 6; F/F, n D 6). Data are presented as mean § SEM. p < 0.05, p < 0.01, p < 0.001. For each group, compared with base-
line or Raji-Ctrl samples, all the differences were statistically significant (p < 0.001). (B–F) Primary cultured NK cells (n D 5/genotype) were isolated upon 18 h co-culture
(2:1) with biotinylated rituximab (RTX-exp)-, obinutuzumab (GA101-exp)-opsonized or non-opsonized Raji (Ctrl-exp) in the presence of medium alone (medium) or, when
indicated, with 20 mM NH4Cl. (B) CD16 surface expression was evaluated by FACS analysis by anti-CD16 (Leu11c) mAb in individuals grouped by FCGR3A genotype. (Top)
Histogram overlay of one representative donor/genotype .is shown and (bottom) normalized CD16 MFI calculated as described in Fig. 2A are depicted in bar graph
(mean § SEM). p < 0.05. (C, E) An equal amount of proteins from whole cell lysates was immunoblotted as indicated. The same membrane was immunoblotted with
anti-FceRIg and, after stripping, with anti-CD3z Abs followed by anti-b-tubulin for sample normalization. Membranes containing untreated- (medium) or NH4Cl-treated
samples were developed in the same film. The black vertical lines indicate that intervening lanes were sliced out. The numbers represent the relative protein amount of
the indicated proteins obtained by normalizing to the level of b-tubulin and expressed as fold change respect to Ctrl-exp samples (arbitrarily set to 1). One representative
experiment is shown. (D, F) The relative values (mean § SEM) of CD3z or FceRIg chains from five independent experiments are depicted in bar graphs.p < 0.05, p <
0.01.
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NK cells were co-cultured for 18 h with anti-CD20-
opsonized targets. Cytotoxic activity of experienced cells
was assessed against FcRC P815 target cells in a redirected
killing assay in the presence of anti-CD16, anti-NKp46,
anti-NKp30 or anti-NKG2D mAbs to explore the killing
ability induced by ITAM-dependent- or ITAM-independent
receptors. We also excluded that, by this time, residual
anti-CD20 could be detected on the surface of NK cells
(not shown). As expected, because of the reduction of
CD16 expression levels, mAb experienced NK cells exhib-
ited a marked reduction of CD16-dependent killing (reverse
ADCC) (Fig. 4A). Moreover, being CD3z and FceRIg chains
the molecular adaptors required for NKp46 and NKp30 sig-
nal transduction,29 we also observed a significant
impairment of NKp46 and NKp30 cytotoxic response, both
in rituximab- and obinutuzumab-experienced NK cells
(Fig. 4A). We also noted a slight reduction of NKp46
expression levels in anti-CD20-experienced cells. On the
opposite, NKG2D-dependent killing, relying on DAP10
adaptor,24 appeared more preserved.
We also analyzed CD107a levels induced by stimulation
with plastic-immobilized mAbs specific for different activating
receptors. Also, in this setting, we observed a significant defect
of degranulation after stimulation of CD16 or NKp46 (Fig. 4B).
No differences with respect to the control population were
observed following stimulation of NKG2D and 2B4, all CD3z-
and FceRIg-independent activating receptors, which are able to
induce degranulation only when stimulated in paired
combinations.37
In line with the lack of CD16 adaptor degradation in
response to rituximab (Fig. 3C), we observed that in F/F donors
NKp46- and NKp30-dependent killing was more preserved in
rituximab- with respect to obinutuzumuab-experienced cells
(Fig. S5).
Obinutuzumab-experienced NK cells exhibit an enhanced
IFNg production
It is well known that cytokine secretion and cytotoxicity can be
uncoupled in target-stimulated NK cells.38 Since the loss of
FceRIg/Syk module has been associated to an increased IFNg
producing potential,39 we explored the ability of anti-CD20-
experienced NK cells to secrete IFNg.
As shown in Fig. 2A, CD16 levels were markedly down-
modulated in the course of interaction with anti-CD20-opson-
ized targets. To obtain, albeit at partial levels, the re-expression
of CD16, we cultured NK cells for 12 h after target detachment.
Figure 4. CD16 engagement by anti-CD20-opsonized targets results in the impairment of FceRIg- and CD3z-dependent NKp46- and NKp30-mediated killing. (A) Primary
cultured NK cells from V/F and V/V individuals (n D 5) were isolated upon 18 h co-culture (2:1) with biotinylated rituximab (RTX-exp)-, obinutuzumab (GA101-exp)-opson-
ized or non-opsonized Raji (Ctrl-exp). Cells were stained as indicated for FACS analysis and tested in 51Cr-release redirected killing assays toward P815 FcRC cells in pres-
ence of Abs for the indicated receptors. (Top) The overlays of histograms from one representative experiment of five performed are shown. (Bottom) Lytic units (LU) from
five independent experiments are shown. Bar graphs depict mean§ SEM. p< 0.05, p< 0.005, p< 0.0005. (B) NK cells as in A were stimulated for 4 h with the indi-
cated plastic-immobilized mAbs. The percentage of CD107aC cells was evaluated by FACS analysis gating on CD56C cells. Data (mean § SEM) from three independent
experiments are shown. p < 0.01, p < 0.001.
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Because of the stronger CD16 downregulation induced by obi-
nutuzumab, the recovery of CD16 expression was significantly
lower in obinutuzumab-experienced NK cells (Fig. 5A).
NK cells were then stimulated for 18 h with non-opsonized
targets, anti-CD20-opsonized targets, IL-12 or IL-2. Exploring
the responsiveness of experienced cells, that we assessed in the
presence of IL-12, we noted that the stimulation with non-
opsonized Raji (Raji-Ctrl) enhances IFNg production in obinu-
tuzumab (3868.7 pg/mL § SEM)- but not in rituximab
(3050.8 pg/mL § SEM)-experienced cells, with respect to con-
trol (2572.25 pg/mL § SEM) population, indicating that obinu-
tuzumab experienced cells are more prone to produce the
cytokine in response to the stimulation of receptors engaged by
ligands expressed by Raji cells (Fig. 5B).40 As reported in
Fig. 1A and B, the stimulation with Raji alone does stimulate
NK cells (not shown).
Regarding the responsiveness to CD16 re-stimulation, we
noted that while mAb-experienced cells failed to respond to rit-
uximab re-stimulation, they significantly respond to obinutuzu-
mab re-stimulation (Fig. 5B). Such enhanced response to
obinutuzumab was largely independent from CD16 levels
(Fig. 5A).
Further, in obinutuzumab-experienced cells, the ability to
produce IFNg in response to IL-12 or IL-2 stimulation is signif-
icantly higher respect to control and rituximab-experienced
populations (Fig. 5C). Such responses were observed across
CD16 genotypes (not shown).
Together these data demonstrate that NK cells that have
encountered obinutuzumab-opsonized targets exhibit a supe-
rior responsiveness to target and cytokine stimulation. More-
over, anti-CD20-experienced cells are able to produce IFNg
only in response to a subsequent obinutuzumab, but not rituxi-
mab, stimulation.
Discussion
Among the Fc-optimized antitumor mAbs, obinutuzumab is
the first glycongineered anti-CD20 mAb approved for clinical
use.3,5 The defucosylation of its Fc portion results in the
enhanced affinity for CD16 and the consequent increased abil-
ity to activate NK cells. Surprisingly, although several preclini-
cal studies showed that obinutuzumab is more potent in
inducing NK cell-mediated tumor target cell killing as com-
pared with the reference mAb, rituximab,6,7,22 no studies
addressed its ability to induce cytokine production by NK cells.
Here, by the simultaneous monitoring of IFNg and CD107a
in individual cells, we assessed the relationship between cyto-
kine production and degranulation induced by the interaction
with obinutuzumab- or rituximab-opsonized targets. We show
that obinutuzumab, used at 10 times lower concentration than
rituximab, stimulates primary NK cells to produce IFNg more
effectively than rituximab, increasing both the proportion of
cells producing IFNg (Fig. 1A and B) and the amount of IFNg
on a per cell basis (Fig. 1C). Moreover, as expected, obinutuzu-
mab was superior to rituximab in the ability to stimulate
degranulation. The enhanced functional activation is conferred
by glycoengineering since the wt mAb promotes significantly
lower IFNg production (Fig. 1A and B). The observation that
wt-GA101 is itself able to induce an increased amount of IFNg
with respect to rituximab indicates that the increased efficacy
of obinutuzumab is not exclusively explained by differences in
Fc portion but also by other characteristics that can affect
CD16 aggregation, such as the lack of the ability to induce
CD20 internalization in obinutuzumab-coated targets.5,22 Clas-
sically, the interaction of NK cells with opsonized targets leads
to the activation of the full NK functional program, i.e., cyto-
toxicity and cytokine production, with an higher activation
threshold (strength and duration of stimuli) required for cyto-
kine secretion when compared with cytotoxicity.24,31 In line
with this notion, we found that the fraction of NK cells that
became cytolytic (as judged by degranulation) following rituxi-
mab or obinutuzumab stimulation, is higher than the fraction
of NK cells that produces IFNg under the same conditions.
Interestingly, in obinutuzumab-stimulated cells, we observed
that the frequency of NK cells performing both degranulation
and IFNg production is proportionally higher (Fig. 1B), indi-
cating that the increased affinity binding enables more cells to
reach the signaling threshold required for IFNg production.
Figure 5. Obinutuzumab-experienced NK cells exhibit an enhanced IFNg production in response to cytokines, targets or obinutuzumab re-stimulation. Primary cultured
NK cells were isolated upon 90 min of co-culture (2:1) with biotinylated rituximab (RTX-exp)-, obinutuzumab (GA101-exp)-opsonized or non-opsonized Raji (Ctrl-exp) and
re-plated for 12 h. (A) NK cells were stained with anti-CD16 (Leu11c) mAb for FACS analysis. Graph depicts CD16 MFI and data are presented as median with the interquar-
tile range. p < 0.01, p < 0.0005. (B) NK cells were re-stimulated (2:1) with non-opsonized targets (Raji-Ctrl), rituximab-opsonized (Raji-RTX) or obinutuzumab-opson-
ized (Raji-GA101) target cells in the presence of IL-12 (10 ng/mL), or (C) left untreated (none) or treated with IL-12 (10 ng/mL) or IL-2 (100 U/mL). After 18 h, supernatants
were collected and assessed for IFNg levels. Data are presented as mean § SEM of seven independent experiments. p  0.05, p  0.01, p  0.0001. Compared to
untreated (none), all the differences were statistically significant (p  0.001).
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Such observations may shed new light on the cytokine release
syndrome reported in obinutuzumab-treated patients41 where a
huge amount of circulating IFNg levels was reported.
In vivo activation of NK cells in rituximab-receiving patients
correlates with the down-modulation of CD16 levels.42,43 Such
response is influenced by the affinity ligation conditions, as it
has not been observed in F/F subjects.43,44
Several groups, including ours, have shown that CD16
down-modulation induced by interaction with rituximab-
opsonized targets may depend on receptor shedding45 and/or
internalization,30 with the relative contribution of each mecha-
nism depending on the engagement conditions (for instance
immobilized versus soluble mAb). Here, we observed that
when CD16 was engaged by obinutuzumab-opsonized targets,
its down-modulation appears more profound and faster with
respect to rituximab, leaving a 17% of residual surface CD16
levels (vs 40% upon rituximab stimulation) (Fig. 2A).
It has been clearly demonstrated that glycoengineered obi-
nutuzumab exhibits higher affinity for CD16 irrespectively of
CD16 allotype.7,22 Indeed, obinutuzumab binds to CD16 var-
iants with an affinity that is higher than that of rituximab for
the high-affinity receptor isoform.7 Accordingly, we observed
that CD16 down-modulation in response to obinutuzumab-
opsonized targets is significantly higher across all CD16 allo-
types, with respect to rituximab (Fig. 3B). This trend strictly
correlates with the induction of degranulation (Fig. 3A),
remarking the link between affinity ligation conditions, recep-
tor down-modulation and functional responses.
The observation of the capability of obinutuzumab to induce
a more efficient decrease of surface CD16 levels is not conflict-
ing with the increased mAb-dependent responses; in fact, the
ability of internalized NK receptors to transmit activating sig-
nals from intracellular compartments before their lysosomal
targeting has been recently reported by our group.46 Indeed, we
observed that, upon 15 min of stimulation, a consistent portion
of internalized receptor appears delivered to the lysosomal
compartment (Fig. 2B and C). The possibility that internalized
CD16 may convey mAb-targeted CD20 into lysosome through
trogocytosis47 requires further investigation. A main finding in
our work is the observation that the interaction with anti-
CD20-opsonized targets promotes the preferential lysosomal
degradation of CD16-associated signaling elements, with affin-
ity ligation conditions dictating the strength and the quality of
the response.
We observed that the levels of FceRIg dramatically fall in
response to obinutuzumab irrespective from CD16 allotype
(Fig. 3C and E), whereas rituximab stimulation is followed by
FceRIg degradation only in intermediate/high affinity donors.
One likely explanation about the preferential degradation of
FceRIg with respect to CD3z chain is the relative abundance of
g/g homodimers respect to g/z heterodimers or z/z homo-
dimers associated to CD16 in human NK cells.28
Ligation-dependent FceRIg and CD3z phosphorylation per-
mits the ITAM-dependent recruitment and activation of Syk
and ZAP-70 tyrosine kinases that subsequently undergo,
together with the engaged receptor complex, to ubiquitin-
dependent degradation.36 Here, we report that the interaction
with anti-CD20-coated targets is followed by the selective deg-
radation of Syk but not ZAP-70 kinase, attributable to the
activation of ubiquitin-dependent pathway. The identification
of the ligase responsible for Syk ubiquitination requires further
investigation.
Interestingly, the downregulation of FceRIg and Syk,
both myeloid cell related signaling proteins, is the hallmark
of the recently described memory-like or adaptive NK
cells.39,48 Such NK cell subset, endowed with a specific epi-
genetic signature, has been expanded in vitro by the anti-
body-mediated recognition of viral antigens, proving that
CD16-driven responses may contribute to calibrate NK
functional potential and response to micro-environmental
challenges.39,49,50
The functional outcome of the downregulation of CD16-
associated signaling elements in obinutuzumab-experienced
cells is an increased potential to produce IFNg in response to
target stimulation or cytokines (Fig. 5B and C), revealing that
CD16 ligation under high-affinity conditions may prime the
cells to a reduced signaling threshold, thereby facilitating stron-
ger effector responses; on this purpose, we are currently investi-
gating the molecular mechanisms involved in NK priming
resulting from high-affinity ligation conditions.
MAb-experienced NK cells appears desensitized to a subse-
quent rituximab re-stimulation, while they efficiently respond
to obinutuzumab re-stimulation likely by virtue of the higher
affinity binding (Fig. 5B). Such response is also observed in obi-
nutuzumab-experienced cells despite a lower residual CD16
levels and a deeper FceRIg deficiency (Fig. 5A).
It is tempting to speculate that, in obinutuzumab-primed
cells, the favored coupling of CD16 to residual CD3z chain
may led to more robust and efficient biochemical signals given
the quantitative differences in ITAM motif (three ITAM in
CD3z vs one ITAM in FceRIg), thus rendering the response
more efficient.
Moreover, the residual levels of CD3z chain observed in
anti-CD20 experienced cells may preserve the co-stimulatory
activity of CD2/CD58 interaction during Raji cell contact.32
We observed that the reduction of FceRIg and, to a lesser
extent of CD3z, along with Syk kinase, dramatically impairs the
ability to kill target cells depending on the engagement of
NKp46 and NKp30 receptors (Fig. 4A), whose signaling ability
relies on such signaling elements.29 The reduced cytolytic
potential that was observed at significant levels both in rituxi-
mab- and obinutuzumab-experienced cells indicates that the
residual CD3z levels are not sufficient to guarantee the optimal
signals required for degranulation. Indeed, the observation of a
defective cytotoxicity in F/F donors, where obinutuzumab
selectively induces the degradation of FceRIg, corroborates the
non-redundant role of such adaptor in ITAM receptor-depen-
dent killing. On this issue, a different coupling of CD3z and
FceRIg chains to downstream signaling intermediates has been
demonstrated.51
Notably, the reduced level of Syk kinase in experienced cells
may also contribute to the killing defect since a non-redundant
role for such kinase has been described both for CD16- and
NCR-dependent killing.52,53
Not very surprising is the observation that in F/F donors, rit-
uximab-experienced cells exhibit a marginal but still significant
defect of NKp30- and NKp46-mediated cytotoxicity despite the
lack of CD16 adaptor degradation; indeed, under low-affinity
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ligation conditions, receptor-driven inhibitory signals may
occur.30
In line with the reduced levels of CD16, we also observed a
reduced ability to execute ADCC in anti-CD20 experienced NK
cells (Fig. 4A); notably, such NK exhaustion may be rescued by
IL-2 treatment, as previously demonstrated by different
groups.54,30
In conclusion, we demonstrate that CD16 ligation by Fc
optimized antitumor mAb obinutuzumab may shift NK func-
tional program toward cytokine production. Taking into
account the capability of mAb-based therapy to prime antitu-
mor long-lasting T-cell responses, the so-called “vaccinal
effect,”55,56 and the well-recognized role of NK-derived IFNg in
promoting DC maturation and the development of adaptive
responses,25-27 NK cells, besides short-term cytotoxic proper-
ties, may be actors in promoting an antitumor response, thus
reducing the risk of tumor-escape and relapse. These preclinical
results appear worthy of further clinical investigation.
Materials and methods
Antibodies
The following anti-CD20 mAbs were used: the chimeric
IgG1k type I rituximab, the humanized IgG1k type II obi-
nutuzumab (GA101) and its non-glycoengineered parental
molecule (wt-GA101) kindly provided by Roche Glycart
(Schlieren, Switzerland); the monovalent Fab fragment of
obinutuzumab (GA101-Fab) obtained by papain digestion
by commercial Fab Preparation kit (Thermo Scientific, code
44985), according to manufacturer’s instructions. Anti-
CD16 (B73.1, provided by Dr. G. Trinchieri National Can-
cer Institute, National Institutes of Health, Frederick, USA),
anti-2B4 (C1.7, Beckman Coulter), anti-NKp46 (9E2, BioLe-
gend), anti-NKG2D (149810, R&D Systems) anti-NKp30
(210847, R&D Systems), goat-anti-mouse (GAM) F(ab’)2
(Jackson Immunoresearch Laboratories). The following fluo-
rochrome-conjugated mAbs for NKG2D (149810, R&D Sys-
tems), CD107a (H4A3, BD Biosciences), CD16 (Leu11c, BD
Biosciences, MEM-154, Immunological Sciences, 3G8, BD
Biosciences), NKp46 (9E2, BD Biosciences), NKp30 (p30-
15, BD Biosciences), CD56 (NCAM16.2, or B159, BD Bio-
sciences), CD3 (SK7, BD Biosciences), IFNg (B27, BD Bio-
sciences) and the goat-anti-human (GAH) k light chain
(Cappel) Ab were used. For immunoblot analysis were used
the following Abs: anti-phosphotyrosine (4G10, Millipore),
anti-FceRIg subunit (Millipore), anti-ZAP-70 (2F3.2, Milli-
pore), anti-ubiquitin (FK2, Enzo Life Sciences), anti-CD3z
(6B10.2, Santa Cruz Biotechnology, Inc.), anti-Syk (4D10
Santa Cruz Biotechnology, Inc.), anti-b-tubulin (Tub2.1,
Sigma-Aldrich).
Cell systems
Peripheral blood mononuclear cells (PBMCs) were freshly iso-
lated from whole peripheral blood samples of healthy donors of
Transfusion Center of Sapienza University of Rome over a
Ficoll-Hypaque gradient. The study was conducted according
to protocols approved by our local institutional review board
and in accordance with the Declaration of Helsinky. Where
indicated, primary cultured human NK cells were obtained
from 10-d co-cultures of PBMC with irradiated Epstein–Barr
virus positive (EBVC) RPMI 8866 lymphoblastoid cell line.57
Experiments were performed on NK cells (CD3¡CD56C) more
than 80% pure.
The following cell lines were used as targets: the human
CD20C lymphoblastoid Raji, provided by Dr. F.D. Batista (Can-
cer Research UK, London) and the murine FcRC mastocytoma
P815, all kept in culture for less than 2 consecutive months in
RPMI 1640 medium supplemented with 10% fetal calf serum
(FCS) and 1% L-glutamine. Cells were counted in a counting
chamber and checked for cell viability by trypan blue staining.
Only samples with viability more than 90% were used. All cell
lines were regularly checked for mycoplasma negativity.
Anti-CD20-mediated CD16 aggregation
CD20C Raji cells were opsonized by incubating with saturating
dose of rituximab (1 mg/106), obinutuzumab (0.1 mg/106), wt-
GA101 (0.1 mg/106) or GA101-Fab (1 mg/106), for 20 min at
room temperature. Non-opsonized Raji, used as control, and
anti-CD20 opsonized targets were washed and allowed to inter-
act with NK cells (E:T D 2:1) for the indicated times.
To obtain anti-CD20 “experienced” NK cells, Raji cells were
loaded with 10 mg/mL of EZ-Link Sulfo-NHS-SS-Biotin
(Thermo Fisher Scientific, code 21331) for 30 min at room tem-
perature and then opsonized with rituximab or obinutuzumab,
as above described. NK cells were mixed (2:1) with targets and
co-cultured for the indicated times and then recovered by nega-
tive selection on streptavidin-coated Dynabeads (Invitrogen,
Life Technologies, code 11047).30 For experiments requiring
lysosomal inhibitor, 20 mM NH4Cl (Sigma-Aldrich, code
A4514) was added during co-culture. Where indicated, anti-
CD20-experienced NK cells were re-plated in culture medium
for up to 48 h.
Cytofluorimetric analysis
To determine the minimum saturating dose of anti-CD20
mAbs, Raji cells (1£106) were incubated with increasing
amounts (0.05 mg, 0.1 mg, 1 mg, 10 mg, 100 mg) of rituximab,
obinutuzumab (GA101), wt-GA101 or GA101-Fab for 20 min
at 4 C and then stained with FITC-conjugated GAH k light
chain Ab.
To determine FcgRIIIA-158V/F allotype, PBMCs from a
cohort of 125 donors were stained with APC-conjugated anti-
CD56 and the following anti-CD16 mAbs: FITC-conjugated
3G8, that binds to a not polymorphic epitope of CD16, or
FITC-conjugated MEM-154, whose binding to CD16 is depen-
dent on the presence of valine.33 The ratio between the mean
fluorescence intensity (MFI) of MEM-154 and 3G8 allows to
classify three different phenotypes: F/F (ratio <0.04), V/V
(ratio >0.62), and V/F (ratio between 0.15 and 0.48).
For CD16-mediated CD107a mobilization and intracellular
IFNg production, NK cells were combined (2:1) with non-
opsonized or anti-CD20-opsonized Raji targets for 6 h at 37 C
in the presence of PE-conjugated anti-CD107a mAb and
50 mM Monensin (Golgi-stop; Sigma-Aldrich, code M5273).
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After the first hour, 10 mg/mL Brefeldin A (Sigma-Aldrich,
code B7651) was added. At the end of stimulation, cells were
washed with PBS supplemented with 5 mM EDTA to obtain
conjugate disruption and, before fixing (2% paraformaldehyde,
Sigma-Aldrich, code 158127), cells were stained with FITC-
conjugated anti-CD56 and PerCP-conjugated anti-CD3 mAbs.
Samples were then permeabilized by incubating for 30 min at
room temperature with 0.5% saponin (Sigma-Aldrich, code
S4521) in PBS supplemented with 1% FCS and then stained
with APC-conjugated anti-IFNg mAb.
To determine CD107a surface expression in response to
activating receptors, anti-CD20-experienced NK populations
were stimulated with plastic-immobilized anti-CD16 (B73.1),
anti-NKG2D, anti-NKp46 and anti-2B4 mAbs, alone or in
combination and treated as described above.
To evaluate CD16 modulation, NK cells were mixed (2:1)
with non-opsonized or anti-CD20-opsonized Raji targets, cen-
trifuged for 1 min at 1000 rpm to allow conjugate formation
and incubated for different times at 37 C. To block the stimu-
lation, samples were treated with 0.1% NaN3 in cold PBS for
5 min on ice and then washed with PBS supplemented with
5 mM EDTA to obtain conjugate disruption. Prior to fix (1%
paraformaldehyde), cells were stained with PE- and APC-con-
jugated anti-CD16 and anti-CD56 mAbs, respectively. Normal-
ized MFI was calculated for each time point as follows: (MFI of
the stimulated sample/MFI of Ctrl sample) £ 100, assuming as
100% the MFI value of NK cells stimulated with non-opsonized
target for each time of stimulation. To examine activating
receptor expression levels, anti-CD20-experienced NK popula-
tions were stained with PE-conjugated anti-CD16, anti-NKp46,
anti-NKp30 or anti-NKG2D mAbs. All results were analyzed
using FlowJo version 9.3.2 software (Tree Star, Ashland, OR).
Confocal microscopy
To evaluate the co-localization of CD16 with the lysosomal com-
partment, NK cells were pre-treated for 30 min at 37 C with
10 mM LysoTracker Red DND-99 (Life Technologies, code L-
7528), and then allowed to interact (2:1) with 7-amino-4-cholro-
methylcoumarin (CMAC)-labeled (Life Technologies, code
C2110) non-opsonized or anti-CD20-opsonized Raji cells. Conju-
gates were gently re-suspended and spun onto poly-L-lysine-coated
glass slides as described previously,58 incubated for 15 min at 37 C
followed by incubation at 4 C for 10 min to promote spontaneous
adhesion. Cells were fixed (3.7% paraformaldehyde), permeabilized
(0.5% saponin), incubated with 0.1 M glycin (Bio-Rad, code 161-
0718) followed by blocking buffer (1% FCS, 0.05% saponin) and
stained with anti-CD16 followed by Alexa Fluor 488-labeled GAM
(Invitrogen) Abs. High-resolution images (800 £ 800 pixel, 8 ms/
pixel) were acquired, on randomly acquired fields, with a IX83
FV1200 laser-scanning confocal microscope (Olympus) with a
60£/1.35 NA UPlanSAPO oil immersion objective. Sequential
acquisition was used to avoid crosstalk between different fluoro-
phores.46 Fluorescence and DIC (Differential Interference Con-
trast) images were acquired with zoom3. Co-localization was
assessed in NK/Raji conjugates (n D 50) showing an extensive
membrane contact between effector and target cells and expressed
as percentage of conjugates containing co-localized CD16 and lyso-
somes with respect to total conjugates, considering co-localization
indexes (Pearson’s correlation coefficient >0.2) obtained by Fluo-
View 4.2 software, between two channels on single cells (ROI) after
background correction. Images were processed with ImageJ1.41o
software.
CD16 polymorphism analysis
Genomic DNA was extracted from PBMCs by commercial
Isolate II Genomic DNA kit (Bioline) in a cohort of 125
healthy donors. The genomic region containing the poly-
morphic c.559 site was amplified by two distinct PCR
assays, as described.34,35 Specifically, for PCR assay 1, PCR
primers: forward1 50-CCCTTCACAAAGCTCTGCACT-30;
reverse1 50-ATTCTGGAGGCTGGTGCTACA-30; sequencing
primer: 50-CCCCAAAAGAATGGACTGAA-30: for PCR
assay 2, PCR primers: forward2 50-TGTAAAACGACGGC-
CAGTTCATCATAATTCTGACCTCT-30, reverse2 50-CAG-
GAAACAGCTATGACCCTTGAGTGATGGTGATGTTCA-
30; sequencing primers: 21M13 or M13. PCR products were
sequenced using the BigDye Terminator v3.1 Cycle
Sequencing Kit and a 3130xl Genetic Analyzer (Thermo
Fisher Scientific) and analyzed by the Sequencing Software
Analysis 6 (Applied Biosystems).
Biochemical analysis
To analyze CD16-associated signaling element expression lev-
els, NK cells were lysed in 1% Triton-X 100 lysis buffer (50 mM
Tris pH7.5, 150 mM NaCl, 1 mM EGTA pH8, 1 mM MgCl2,
50 mM NaF, 1 mM PMSF, 1 mM Na3VO4) supplemented with
1 mg/mL each of aprotinin, leupeptin and when required with
5 mM N-ethyl-maleimide. Equal amount of proteins from each
sample were separated by SDS-PAGE and transferred to nitro-
cellulose for immunoblot analysis. To explore Syk ubiquitina-
tion, CD16 stimulation was obtained by mixing primary
cultured human NK cells with non-opsonized or anti-CD20-
opsonized Raji cells for the indicated times. Before mixing, tar-
gets cells were fixed (0.5% paraformaldehyde) for 5 min at
room temperature, washed three times in complete medium,
incubated at 37 C for 1 h and washed once more. At the end
of stimulation, samples were lysed as above described and
immunoprecipitated with anti-Syk-pre-loaded protein G
Sepharose beads (Sigma-Aldrich, code P3296).
Evaluation of cytotoxic activity and IFNg release
For ADCC activity, rituximab- or obinutuzumab-opsonized or
non-opsonized 51Cr-labeled Raji were used as targets. For redir-
ected killing assay, NK cells were incubated with FcRC P815
targets in the presence of anti-CD16, anti-NKp46, anti- NKp30
or anti-NKG2D mAbs.
Maximal and spontaneous release was obtained by incubating
51Cr-labeled individual targets, as used for each stimulation condi-
tion, with SDS 10% or medium alone, respectively. The percentage
of specific lysis was calculated according to the formula: percentage
of specific release D (experimental-spontaneouns release)/(total-
spontaneous release) £ 100. Lytic units for 1 £ 106 effector cells
were calculated as follows: 1£ 106 /(no. of target cells£ X), where
X is the E:T ratio resulting in 10% specific lysis.
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For IFNg release, anti-CD20-experienced NK cells were
mixed (2:1) with the indicated targets in the presence or
absence of recombinant human IL-12 (10 ng/mL) (Peprotech,
code 200–12) or IL-2 (100 U/mL) (R&D Systems, code 202-IL),
for 18 h. Supernatants were collected and analyzed by commer-
cial ELISA kit (Thermo Scientific, code EHIFNG2), according
to the manufacturer’s instructions.
Statistical and densitometric analysis
Differences among multiple groups were compared by one-way
ANOVA with Tukey post-test correction, by Friedman with
Dunn’s post-test correction, or by two-way ANOVA with Bon-
ferroni post-test correction, as appropriated. Differences
between two groups were determined by performing Wilcoxon
matched pairs test. Differences were considered to be statisti-
cally significant when p value was less than 0.05. Analyses were
performed using Prism 5 software (GraphPad). Quantification
of specific bands was performed with ImageJ1.41o software
(National Institutes of Health, Bethesda, MD).
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